Kelleher Financial Advisors Acquires 4,797 Shares of Pfizer Inc. $PFE

Kelleher Financial Advisors boosted its holdings in Pfizer Inc. (NYSE:PFE) by 12.0% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 44,793 shares of the biopharmaceutical company’s stock after buying an additional 4,797 shares during the quarter. Kelleher Financial Advisors’ holdings in Pfizer were worth $1,086,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in PFE. Vanguard Group Inc. lifted its stake in Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after purchasing an additional 4,629,976 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Pfizer by 6.8% during the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock worth $1,579,340,000 after buying an additional 3,943,397 shares in the last quarter. Amundi lifted its stake in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares during the last quarter. Invesco Ltd. grew its position in Pfizer by 2.8% during the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company’s stock worth $767,709,000 after acquiring an additional 838,198 shares during the last quarter. Finally, Deutsche Bank AG increased its holdings in Pfizer by 7.0% in the 1st quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company’s stock worth $715,581,000 after purchasing an additional 1,846,436 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a research report on Friday, October 31st. UBS Group restated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Morgan Stanley decreased their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.18.

Pfizer Stock Performance

NYSE:PFE opened at $25.49 on Wednesday. The firm has a market capitalization of $144.93 billion, a P/E ratio of 13.56, a P/E/G ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The company has a fifty day moving average of $24.75 and a 200-day moving average of $24.41. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.